Royal Bank Of Canada Aligos Therapeutics, Inc. Transaction History

Royal Bank Of Canada

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.35 - $1.07 $135 - $414	387 Added 312.1%	511 $0
Q1 2024 Nov 05, 2024	SELL	$0.64 - $1.13 $247 - $437	-387 Reduced 75.73%	124 $0
Q1 2024 May 15, 2024	SELL	$0.64 - $1.13 $202 - $358	-317 Reduced 71.88%	124 $0
Q4 2023 Feb 14, 2024	SELL	$0.56 - $0.8 $360,702 - $515,289	-644,112 Reduced 99.93%	441 $0
Q3 2023 Nov 14, 2023	SELL	$0.71 - $1.06 $139,046 - $207,590	-195,840 Reduced 23.3%	644,553 $483,000
Q2 2023 Aug 14, 2023	BUY	$0.89 - $1.36 $708,153 - $1.08 Million	795,678 Added 1779.44%	840,393 $815,000
Q1 2023 May 15, 2023	BUY	$0.87 - $2.11 $38,886 - $94,310	44,697 Added 248316.67%	44,715 $38,000
Q4 2022 Feb 14, 2023	BUY	$0.89 - $28.0 $4 - $140	5 Added 38.46%	18 $0
Q2 2022 Aug 15, 2022	SELL	$1.04 - $2.14 $1,349 - $2,777	-1,298 Reduced 99.01%	13 $0
Q1 2022 May 16, 2022	SELL	$2.08 - $12.2 $6,346 - $37,222	-3,051 Reduced 69.94%	1,311 $3,000
Q4 2021 Feb 14, 2022	BUY	$11.48 - $17.69 $29,779 - $45,887	2,594 Added 146.72%	4,362 $52,000
Q3 2021 Nov 15, 2021	BUY	$14.57 - $17.72 $7,051 - $8,576	484 Added 37.69%	1,768 $27,000
Q2 2021 Aug 16, 2021	BUY	$20.3 - $33.6 $26,065 - $43,142	1,284 New	1,284 $26,000

253K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $751M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.